1 Min Read
June 29 (Reuters) - Teva Pharmaceutical Industries Ltd
* Publication of AIM-TD study results in lancet psychiatry for investigational use of deutetrabenazine in tardive dyskinesia Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.